You are viewing the site in preview mode
Skip to main content
|
Characteristic
|
Total sample (N = 2313)
|
Cannabis non-user (n = 1135)
|
Cannabis user (n = 1178)
|
|---|
|
Demographic
| | | |
|
Age in years; mean (SD)
|
39.3 (10.9)
|
40.9 (10.9)
|
37.7 (10.6)
|
|
Female sex; n (%)
|
1025 (44.3%)
|
557 (49.1%)
|
468 (39.7%)
|
|
Married; n (%)
|
673 (29.1%)
|
356 (31.4%)
|
317 (26.9%)
|
|
Unemployed; n (%)
|
1548 (66.9%)
|
761 (67.1%)
|
787 (66.8%)
|
|
Clinical
| | | |
|
Length of time in treatment, in years; median (Q1, Q3)
|
2.6 years (0.83, 6)
|
3 years (0.92, 7)
|
2 years (0.75, 6)
|
|
Type of treatment; n (%)
| | | |
|
Methadone
|
1833 (79.4%)
|
890 (78.6%)
|
944 (80.1%)
|
|
Buprenorphine–naloxone
|
477 (20.7%)
|
243 (21.5%)
|
234 (19.9%)
|
|
Medication dose in mg/day; mean (SD)
| | | |
|
Methadone
|
70.4 mg (40.6)
|
72.9 mg (41.3)
|
68.1 mg (39.8)
|
|
Buprenorphine–naloxnaloxone
|
12 mg (6.8)
|
12 mg (7.0)
|
12 mg (6.6)
|
|
Opioid use at 3 monthsa; n (%)
|
1015 (44.8%)
|
488 (44.0%)
|
527 (44.7%)
|
|
Percentage of opioid-positive urine drug screens amongst users; median (Q1, Q3)
|
25 (11.1, 50)
|
30 (12.5, 55.6)
|
21.4 (10, 50)
|
- SD standard deviation, MAT medication-assisted treatment, Q1 25th percentile, Q3 75th percentile
- aData available for n = 1155 participants
